Sinovac Biotech, Operating Income

Sinovac Biotech, (SVA) currently reports a operating income of $-1B as of December 2023. That compares with $18B in the prior-year period — down 105.7% year over year. Use the charts on this page to explore Sinovac Biotech,'s operating income history and peer comparisons.

Sinovac Biotech,'s operating income decreased from $18B to $-1B — a 105.7% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sinovac Biotech, reported $-1B in operating income as of December 2023. That compares with $18B in the prior-year period — down 105.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.

Sinovac Biotech, is classified in the Healthcare sector. On operating income, it currently shows $-1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SVA with unrelated industries.